Keyna Skeffington - LivaNova PLC Senior Vice President General Counsel
| LIVN Stock | USD 50.69 1.06 2.05% |
President
Ms. Keyna Pidcock Skeffington is Senior Vice President, General Counsel of the Company. Previously, Ms. Skeffington served in various roles at Medtronic Plc from 2004 to 2017, most recently as Vice President of Legal Corporationrationrate and Securities from 2006 to 2017. She also served as Assistant Secretary from 2004 to 2017 and Senior Legal Counsel for Medtronics Cardiac Surgery Business from 2005 to 2006. Before Medtronic, Ms. Skeffington was a Partner at Faegre Baker Daniels LLP since 2017.
| Age | 61 |
| Tenure | 7 years |
| Address | 20 Eastbourne Terrace, London, United Kingdom, W2 6LG |
| Phone | 44 20 3325 0660 |
| Web | https://www.livanova.com |
LivaNova PLC Management Efficiency
The company has return on total asset (ROA) of 0.0434 % which means that it generated a profit of $0.0434 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0187 %, meaning that it created $0.0187 on every $100 dollars invested by stockholders. LivaNova PLC's management efficiency ratios could be used to measure how well LivaNova PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, LivaNova PLC's Return On Tangible Assets are very stable compared to the past year. As of the 28th of November 2024, Return On Assets is likely to grow to 0.01, while Return On Capital Employed is likely to drop (0.03). At this time, LivaNova PLC's Intangible Assets are very stable compared to the past year. As of the 28th of November 2024, Net Tangible Assets is likely to grow to about 116.1 M, while Deferred Long Term Asset Charges is likely to drop about 4.8 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Stanley Peters | CONMED | 45 | |
| Terence Berge | CONMED | 54 | |
| Keith Pfeil | Globus Medical | 45 | |
| Daniel Jonas | CONMED | 56 | |
| Patrick Beyer | CONMED | 58 | |
| Mark Munch | Bruker | 62 | |
| Jim Stephens | Integer Holdings Corp | 50 | |
| Stanley III | CONMED | 49 | |
| Mark Day | iRhythm Technologies | 53 | |
| Anthony Borowicz | Integer Holdings Corp | 67 | |
| Tyler Lipschultz | Orthofix Medical | 57 | |
| Kimberley Elting | Orthofix Medical | 59 | |
| Jason Garland | Integer Holdings Corp | 50 | |
| John Kennedy | CONMED | 66 | |
| Tom Thomas | Integer Holdings Corp | 53 | |
| Craig Hunsaker | Alphatec Holdings | 60 | |
| Jon Serbousek | Orthofix Medical | 63 | |
| Gregory Odle | Orthopediatrics Corp | 54 | |
| David Demski | Globus Medical | 62 | |
| Kelli Howell | Alphatec Holdings | 50 | |
| Joel Becker | Integer Holdings Corp | 53 | |
Management Performance
| Return On Equity | 0.0187 | ||||
| Return On Asset | 0.0434 |
LivaNova PLC Leadership Team
Elected by the shareholders, the LivaNova PLC's board of directors comprises two types of representatives: LivaNova PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LivaNova. The board's role is to monitor LivaNova PLC's management team and ensure that shareholders' interests are well served. LivaNova PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LivaNova PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lindsey Little, Director Relations | ||
| Damien McDonald, CEO Director | ||
| Alex CMA, Chief Officer | ||
| William Kozy, Chairman CEO | ||
| Stephanie Bolton, President Epilepsy | ||
| Matthew III, Senior IT | ||
| Badri Amurthur, Chief Officer | ||
| Trui Hebbelinck, Chief Human Resource Officer | ||
| Deanna Wilke, Vice Communications | ||
| Paul Buckman, President Replacement | ||
| John Webb, Vice Epilepsy | ||
| Keyna Skeffington, Senior Vice President General Counsel | ||
| Michael Hutchinson, Chief VP | ||
| Ryan Miller, President Support | ||
| Alex Shvartsburg, Chief Officer | ||
| Ahmet Tezel, Chief Officer | ||
| Bryan Olin, Senior Neuromodulation | ||
| Vladimir Makatsaria, CEO Director | ||
| Marco Dolci, Pres Unit | ||
| Jonathan Walker, VP Segment | ||
| Franco Poletti, President Unit |
LivaNova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LivaNova PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0187 | ||||
| Return On Asset | 0.0434 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 3.18 B | ||||
| Shares Outstanding | 54.3 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 99.70 % | ||||
| Number Of Shares Shorted | 2.36 M | ||||
| Price To Earning | 78.67 X |
Pair Trading with LivaNova PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if LivaNova PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in LivaNova PLC will appreciate offsetting losses from the drop in the long position's value.Moving against LivaNova Stock
| 0.77 | HUM | Humana Inc Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.64 | XYLO | Xylo Technologies Symbol Change | PairCorr |
| 0.54 | ELV | Elevance Health Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.49 | CI | Cigna Corp | PairCorr |
| 0.46 | CNC | Centene Corp Sell-off Trend | PairCorr |
The ability to find closely correlated positions to LivaNova PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace LivaNova PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back LivaNova PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling LivaNova PLC to buy it.
The correlation of LivaNova PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as LivaNova PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if LivaNova PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for LivaNova PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LivaNova PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in LivaNova Stock, please use our How to Invest in LivaNova PLC guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LivaNova PLC. If investors know LivaNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LivaNova PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.43 | Revenue Per Share 22.907 | Quarterly Revenue Growth 0.112 | Return On Assets 0.0434 |
The market value of LivaNova PLC is measured differently than its book value, which is the value of LivaNova that is recorded on the company's balance sheet. Investors also form their own opinion of LivaNova PLC's value that differs from its market value or its book value, called intrinsic value, which is LivaNova PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LivaNova PLC's market value can be influenced by many factors that don't directly affect LivaNova PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LivaNova PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if LivaNova PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LivaNova PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.